Kineta, Inc. (KANT)

OTCMKTS · Delayed Price · Currency is USD
0.336
+0.046 (15.90%)
Inactive · Last trade price on Jun 27, 2025
-42.04%
Market Cap 4.55M
Revenue (ttm) n/a
Net Income (ttm) -8.57M
Shares Out 13.54M
EPS (ttm) -0.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 360
Average Volume 23,292
Open 0.304
Previous Close 0.290
Day's Range 0.304 - 0.337
52-Week Range 0.181 - 1.150
Beta -2.72
RSI 61.34
Earnings Date Aug 8, 2025

About Kineta

Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients’ lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 5
Stock Exchange OTCMKTS
Ticker Symbol KANT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.